The present invention relates to a composition for cryopreservation, comprising: a nucleic acid structure which comprises a scaffold nucleic acid folded at predetermined positions to form multiple strands, and a plurality of staple nucleic acids wherein at least a portion of a sequence thereof comprises a complementary sequence to that of the scaffold nucleic acid, which are bound to at least one of the strands of the scaffold nucleic acid to form a double strand; linkers coupled to at least one of single strands in the nucleic acid structure; and an anti-freezing peptide coupled to at least one of the linkers, so as to exhibit excellent freeze-protection effects, which in turn increase cell viability during cryopreservation of cells and tissues, while retaining original texture of food even when used for freezing the food.

The present disclosure provides tissue matrix packaging devices and methods of use. The packaging can be used to help a tissue matrix sample retain its shape when being stored or transported.

The present disclosure provides tissue matrix packaging devices and methods of use. The packaging can be used to help a tissue matrix sample retain its shape when being stored or transported.

Provided are a decellularized amniotic membrane matrix hydrogel and its preparation method, which includes the following steps: pre-treatment of an amniotic membrane tissue, washing, decellularization, grinding, freeze-drying, digestion, and acid-base neutralization processes. The decellularized amniotic membrane matrix hydrogel provided in this disclosure retains components such as collagen, fibronectin, and glycoproteins from the amniotic membrane while removing viable cells, thereby reducing its immunogenicity at the source. The decellularized amniotic membrane matrix hydrogel may mimic the microenvironment in which cells exist in vivo, providing the necessary support and signals for cell adhesion and growth. It can be used to construct tissue engineering scaffolds, supporting directed cell growth and tissue regeneration. Furthermore, the decellularized amniotic membrane matrix hydrogel may also serve as a drug carrier for in vivo drug release and therapy, demonstrating significant potential for application in medical research and clinical settings.

A cryoprotective composition configured to be applied during cryotreatment of a patient includes at least one biodegradable and/or bioerodible fluid agent and at least one non-toxic cryoprotectant agent. A therapeutically effective amount of the cryoprotective composition deposited in a body space of the patient in proximity to the cryotreatment remains within at least a portion of the body space for a duration of the cryotreatment. At least a portion of a body tissue proximate to the body space is viable after the cryotreatment. A method of protecting a surgical site during prostate cryosurgery is also provided. The method includes injecting a therapeutically effective amount of the cryoprotective composition into the body space, wherein the body space is a periprostatic space of a patient.

A cryoprotective composition configured to be applied during cryotreatment of a patient includes at least one biodegradable and/or bioerodible fluid agent and at least one non-toxic cryoprotectant agent. A therapeutically effective amount of the cryoprotective composition deposited in a body space of the patient in proximity to the cryotreatment remains within at least a portion of the body space for a duration of the cryotreatment. At least a portion of a body tissue proximate to the body space is viable after the cryotreatment. A method of protecting a surgical site during prostate cryosurgery is also provided. The method includes injecting a therapeutically effective amount of the cryoprotective composition into the body space, wherein the body space is a periprostatic space of a patient.

Systems and methods are disclosed relating to extracorporeal fetal care. A fetal chamber assembly configured to enclose and support a fetus therein includes a base configured to receive the fetus therein; a lid configured to removably contact the base to form a liquid-tight seal between the lid and the base; a growth chamber defined between the base and the lid, the growth chamber being configured to receive the fetus therein; and a cannulation chamber in fluid communication with the growth chamber, the cannulation chamber being configured to receive therein a cannulated umbilical cord of the fetus. The growth chamber is configured to be adjusted in size to accommodate the fetus during gestation based on the size of the fetus, and the fetal chamber assembly is configured to receive a liquid from a liquid source.

Systems and methods are disclosed relating to extracorporeal fetal care. A fetal chamber assembly configured to enclose and support a fetus therein includes a base configured to receive the fetus therein; a lid configured to removably contact the base to form a liquid-tight seal between the lid and the base; a growth chamber defined between the base and the lid, the growth chamber being configured to receive the fetus therein; and a cannulation chamber in fluid communication with the growth chamber, the cannulation chamber being configured to receive therein a cannulated umbilical cord of the fetus. The growth chamber is configured to be adjusted in size to accommodate the fetus during gestation based on the size of the fetus, and the fetal chamber assembly is configured to receive a liquid from a liquid source.